EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Does Gluco6 really work… or is it just another overhyped capsule making big promises? The claims are bold. According to the ...

Take one capsule daily, preferably with a full meal and a glass of water. For best results, take Gluco6 consistently for 30 ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Delcath's Q4 sales exceeded expectations due to HEPZATO KIT adoption. Discover insights into its profitability, CHOPIN trial ...

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its ...